Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

B-M EXEC VPs BRUCE GELB AND WILLIAM MILLER GET "EXPANDED" ROLES under an organizational shift in top management announced by the company May 15. The realignment, effective Sept. 1, will coincide with the departure of Health Care Group President James Tuholski, PhD, who is taking early retirement. Since late 1981, the three, with the title of group president, have headed the company's main business groups. Gelb picks up responsibility for the company's health care group in addition to his current overall responsibility for Bristol-Myer's consumer products group, the release explained. Promoted under the reorganization and reporting to Gelb will be former Drackett Div. President Nicholas Evans, who takes over as consumer product group president, and former Senior VP Planning and Development Charles Heimbold Jr., who will head the health care group. Miller retains responsibility for the firm's worldwide pharmaceutical and nutritional businesses. However, under the reorganization, the three divisions headed by Miller have been elevated to group status, with the head of each division assuming the title of group president and reporting to Miller. Wayne Davidson will serve as president of the U.S. pharmaceutical and nutritional group; Joseph Maroun will assume the title of president of Bristol-Myers internatl. group, and Abramo Virgilio, PhD, will be president of the firm's science and technology group.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts